Menu

Docusate

Also known as: Docusate sodium, Docusate calcium

A stool-softener medicine with familiar label uses and limited clinical evidence, including a negative add-on trial in hospice patients.

A tissue-paper and gouache collage of a milky liquid pool on an unmarked ceramic tile.
Editorial illustration

Docusate is a stool-softener medicine used for short-term constipation. Its use is familiar, but the clinical evidence is limited. In a randomized hospice trial, adding docusate to sennosides did not significantly improve the main bowel outcomes compared with adding placebo. That particular finding needs to retain its palliative-care and combination-treatment context.2, 3, 4

  • The cited U.S. label contains 100 mg docusate sodium per softgel and identifies occasional constipation as its use.1
  • The 2013 hospice trial randomized 74 patients and compared two sennoside-containing regimens for ten days.3
  • The 2015 Cochrane palliative-care review found a small, heterogeneous evidence base that could not support a pooled comparison of laxatives.4

What is Docusate?

Docusate products come in several oral forms. This guide uses one current U.S. sodium-softgel label for product details and separates that label from evidence about clinical effectiveness. Directions vary across products, so the ingredient name alone cannot specify how an individual preparation should be used.2, 1

Where it comes from

Natural sources

  • The cited medication sources concern manufactured pharmaceutical preparations.

How it's made

The sodium salt is the active ingredient in the specific softgel label assessed here.

What it does in products

  • Stool-softener laxative active in oral medicines

Benefits

The common use has limited trial support

limited evidence

The available findings leave important uncertainty about who benefits.3, 4

In the ten-day hospice trial, docusate added to sennosides did not significantly improve stool frequency, volume, consistency or perceived evacuation. The Cochrane review also found limited palliative-care evidence. These sources neither establish a general benefit nor test every occasional-constipation setting.

Evidence scope and limitations

Oral docusate, one current U.S. sodium-softgel label, NLM medication guidance and selected palliative-care evidence.

  • The original hospice study was assessed through its abstract because publisher full text was unavailable.
  • The study tested docusate added to sennosides for ten days. It does not settle effectiveness alone, in other populations or over longer periods.
  • The older Cochrane review is retained for its specific setting. This is not an exhaustive review of every salt, route or constipation regimen.

Evidence last checked: 2026-11-13

Side effects & safety

Cramps, nausea or oral-liquid throat irritation (varies)MedlinePlus identifies these possible effects. Persistent or severe symptoms require advice, and the oral-liquid warning should retain its formulation context.

Safety considerations

  • The cited label directs pregnant or breastfeeding users to a health professional before use.
  • The label warns against concurrent mineral oil unless a doctor directs it. MedlinePlus also advises reviewing medicines and supplements with a clinician or pharmacist.
  • Not for: Seek advice before use for abdominal pain, nausea, vomiting or a bowel-habit change lasting more than two weeks.
  • Not for: The label calls for stopping and obtaining advice for rectal bleeding, no bowel movement after use or a need for laxatives beyond one week.
2, 1

Amounts studied & product use

These figures describe research or common product use, not a personal dose or treatment recommendation.

In oral stool-softener products

The cited 100 mg softgel label gives 1–3 softgels daily for adults and people aged 12 or older, with a full glass of water. This is product-label context, not a personal dose or a direction for liquid, calcium-salt or rectal products. The clinical comparison described above lasted ten days under study supervision.

1, 3

Regulatory status

  • The cited DailyMed record identifies a U.S. OTC drug label under monograph M007. It documents that formulation's directions and warnings. A label listing does not establish the strength of clinical benefit or product-specific FDA approval.
1

What the negative trial can answer

Both trial groups received sennosides. The comparison therefore tested the extra contribution of docusate in that regimen. Its negative result cannot isolate the effect of docusate alone in otherwise healthy adults.

The broader palliative-care review could not pool the varied treatments. A treatment's popularity and a familiar stool-softener mechanism do not resolve this evidence gap. Decisions still need the patient's setting, bowel symptoms and observed response.

3, 4

Frequently asked questions

Does docusate act immediately?

The cited label describes a usual onset within 12–72 hours, and MedlinePlus describes one to three days. Those are product-use expectations and do not establish that every episode of constipation will respond.1, 2

The bottom line

Keep the exact preparation and patient setting visible when weighing docusate's familiar use against its limited evidence.

References

  1. Docusate sodium 100 mg softgel — Drug Facts. Cardinal Health 107, LLC / DailyMed (2026) · ingredient monograph · SPL set ID fc5e82b6-e25c-4686-9781-2205819685f5; updated July 20, 2026; product-specific repackaged label, not a recommendation
  2. Stool Softeners. MedlinePlus / U.S. National Library of Medicine · ingredient monograph · Current patient medication information checked November 13, 2026; source publication year not assigned
  3. Tarumi Y, Wilson MP, Szafran O, Spooner GR. Randomized, double-blind, placebo-controlled trial of oral docusate in the management of constipation in hospice patients. Journal of Pain and Symptom Management (2013) · randomized trial · PMID 22889861; DOI 10.1016/j.jpainsymman.2012.02.008; 2013 journal issue, online August 11, 2012; original abstract checked, full text unavailable
  4. Candy B, Jones L, Larkin PJ, et al.. Laxatives for the management of constipation in people receiving palliative care. Cochrane Database of Systematic Reviews (2015) · systematic review · PMID 25967924; DOI 10.1002/14651858.CD003448.pub4; published May 13, 2015; limited heterogeneous palliative-care evidence, retained for this specific population

Revision history

  1. Initial AI-assisted source compilation with claim-level citations, formulation distinctions and explicit evidence limitations; not independent medical review.